Please select the eligibility criteria that correspond to the clinical trial below.
Title: Resistance Training in Radically Treated Respiratory Cancer Patients: a Prospective Randomized Multicenter Study
Brief Summary: The first part of the study is an observational part. In eligible patients with early stage respiratory cancer, the primary and secondary endpoints will be evaluated before and after their scheduled radical cancer therapy. The measured variables, include a blood sample, pulmonary function tests, level of dyspnea, exercise tests, measurement of body composition, respiratory and peripheral muscle force, health related quality of life and psychological status. Only registered participants having completed a radical treatment and having either less than 70% of the predicted normal value of the quadriceps force (QF) or a decrease of more than 10% predicted value of the QF between pre-and post radical treatment, will be allowed to participate to the second part of the study. These patients will then be randomized in three groups. Group A, the control group, will have the usual care and follow up according to clinical symptoms. Group B will be offered a conventional resistance training program (CRT), and group C, will be offered a whole body vibration resistance training (WBV) on the FITVIBE-platform. All previous variables will be measured after 6 and 12 weeks of training.


Options:
A: Inclusion Criteria:

* Histologically diagnosed with lung cancer
* Stage I, II, or III
* Eligible for chemotherapy with curative intent
* 21 years of age or older
* Approval to participate in study by treating oncologist or family physician

Exclusion Criteria:

* Unstable cardiac disease
* Untreated bone or brain metastases
B: Inclusion Criteria:

* NSCLC stage IIIB/IV
* receiving systemic treatment (palliative radiotherapy accepted)
* BMI \> 18
* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
* signed informed consent

Exclusion Criteria:

* serious active infection (i.e. requiring an iv antibiotic, antifungal or antiviral agent)
* inability to walk
* immobility (more than two days)
* previously untreated (non-irradiated or non-resected) symptomatic brain metastases;permitted are: (1) previously treated brain metastases \[radiotherapy, surgery, dexamethasone dosage 8 mg per day, anti-epileptic therapy\]; (2) asymptomatic brain metastases without additional therapy requirement
* severe neurologic impairment (e.g. apoplectic insult, Morbus Parkinson, pareses of extremities)
* severe cardiac impairment (e.g. cardiac insufficiency NYHA (New York Heart Association) \> III, myocardial infarction within the last three months, unexplained syncopal events, severe cardiac arrhythmias, high grade aortic stenosis)
* severe respiratory insufficiency
* uncontrolled pain
* abuse of alcohol or drugs reducing compliance to the study
* bone metastasis inducing skeletal fragility
* any circumstance that would impede ability to give informed consent or adherence to study requirements.
C: Inclusion Criteria:

* Non small cell lung cancer stage IIIb-IV
* Small cell lung cancer Extensiv disease
* Patients \>18 years
* WHO performance status 0-2
* undergoing chemotherapy

Exclusion Criteria:

* brain or bone metastases;
* prolonged bone marrow suppression
* anti-coagulant treatment
* symptomatic heart disease
* congestive heart failure
* arrhythmia
* myocardial infarction diagnosed within the last three months
* inability to provide informed consent.
D: Inclusion Criteria:

* Patients with non-small cell or small cell lung cancer or mesothelioma candidate for radical treatment

  * either by surgical resection with or without perioperative chemotherapy
  * or by thoracic radiotherapy with or without chemotherapy
* Between 18 and 80 years of age
* Written informed consent

Supplementary criteria for PART II:

* Treatment for their cancer considered radical

  * either by surgical resection with or without perioperative chemotherapy
  * or by thoracic radiotherapy with or without chemotherapy
* having less than 70% of the predicted normal value of the Quadriceps Force (QF) or a decrease of more than 10% predicted value of the QF between the baseline and post-radical therapy measurement of QF
* Post treatment assessment maximum 14 days after radical treatment or between 6th and 8th week after radical treatment if the latter consists only of surgical resection

Exclusion Criteria:

Patients presenting with one or more of the following will be excluded:

* Severe anemia (Hb below 8 g/dl)
* Fever (\> 38°C)
* Cachexia (loss of more than 35% of premorbid weight)
* Severe cardiac, neurological and orthopedic co-morbidity interfering with exercise training.
* A pacemaker, hip, knee of shoulder prosthesis or recently introduced spirals, metal pens, bolts or plates
* Uncontrolled diabetes, epilepsy or migraine
* Uncontrolled vertebral diseases (osteoporotic or metastatic fractures, acute hernia, discopathy, spondylitis)
* Open wounds

Answer: D